Botulinum Neurotoxins Antibody and Vaccine

Message from the Guest Editors

Dear Colleagues,

Botulinum neurotoxins (BoNTs) are true miracle protein molecules created by nature, which embody the biological functional beauty of yin and yang in the same structure. On the one hand, they are the most toxic substances known to human being, and are listed as one of the six highest-risk threat agents for bioterrorism in the USA, and they could cause botulism, a deadly human and animal disease if not treated timely. On the other hand, they are the key components of several widely used government approved medicines. To mitigate the potential risk of BoNTs, while making full use of their therapeutic powers for the ever-expanding list of human diseases, rationally-designed and applied antitoxins or vaccines seem to be the best option to accomplish this task. In this Special Issue of “Botulinum Neurotoxins Antibody and Vaccine”, the most up-to-date research and investigation on counter-measures for botulism are compiled, and the possible unwanted neutralizing antibody reaction issues in BoNT therapeutic targets are also discussed.

Prof. Dr. Jianlong Lou
Prof. Dr. James D. Marks
Guest Editors

mdpi.com/si/6693
Editor-in-Chief

Prof. Jay Fox
Department of Microbiology,
University of Virginia,
Charlottesville, VA, USA

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of Toxins are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider Toxins when submitting your work for publication.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases. Full-text available in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Toxins
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/toxins
toxins@mdpi.com
@Toxins_Mdpi